Rimegepant (** Nurtec ODT (orally disintegrating tablet) **)
Other Medications
Description
Rimegepant is not indicated for the treatment of colorectal cancer. It is used as an acute treatment for migraine and cluster headache in adults, with efficacy demonstrated in clinical trials showing rapid onset of action and sustained relief without sedation or cardiovascular effects.
Mechanism of Action
Rimegepant is a small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, which plays a role in migraine pathophysiology by mediating neurogenic inflammation and pain.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ** Nurtec ODT (orally disintegrating tablet) ** |
| Category | Other Medications |
 EMA Status | Not submitted to EMA |
 Spain Access | Not funded other indication |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.